NexGel (NASDAQ:NXGL – Get Free Report) and iRadimed (NASDAQ:IRMD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Profitability
This table compares NexGel and iRadimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NexGel | -28.54% | -64.29% | -29.64% |
| iRadimed | 26.70% | 23.45% | 20.36% |
Earnings and Valuation
This table compares NexGel and iRadimed”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NexGel | $11.42 million | 0.40 | -$3.00 million | ($0.40) | -1.24 |
| iRadimed | $83.81 million | 13.30 | $22.48 million | $1.79 | 48.67 |
iRadimed has higher revenue and earnings than NexGel. NexGel is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
2.2% of NexGel shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 23.4% of NexGel shares are held by company insiders. Comparatively, 34.6% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for NexGel and iRadimed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NexGel | 1 | 0 | 1 | 0 | 2.00 |
| iRadimed | 0 | 2 | 2 | 1 | 2.80 |
NexGel currently has a consensus price target of $2.00, suggesting a potential upside of 302.41%. iRadimed has a consensus price target of $120.00, suggesting a potential upside of 37.74%. Given NexGel’s higher probable upside, analysts clearly believe NexGel is more favorable than iRadimed.
Risk & Volatility
NexGel has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Summary
iRadimed beats NexGel on 14 of the 15 factors compared between the two stocks.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Receive News & Ratings for NexGel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexGel and related companies with MarketBeat.com's FREE daily email newsletter.
